Europe's pharma sector now trails the US, it went on to say, "on every investor metric from availability of capital, ...

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened US tariffs on imports, ...

Pharma companies are leveraging the United States’ threat of tariffs on drug imports to push for policy changes in the EU. | Pharma companies are leveraging the Trump administration’s threat of ...

President Trump unveiled a wide-ranging executive order that aims to lower drug prices, boost transparency into fees charged ...

Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

The EU’s top trade official is pressing on with negotiations in a bid to de-escalate a trade war, but some EU rules are not ...

A drug that targets an underlying cause of Alzheimer's disease being commercialized by Eisai and Biogen has received marketing approval from the European Commission.

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...